Suppression of the vascular response to injury

The role of angiotensin-converting enzyme inhibitors

Jerry S Powell, Rita K M Muller, Hans R. Baumgartner

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Smooth muscle cell proliferation and formation of extracellular matrix are parts of the repair process after vascular injury. Similar processes occur after coronary angioplasty and, in approximately 33% of vessels, lead to intimal hyperplasia and vascular restenosis within 6 months after angioplasty. In a rat model of balloon catheterization, the proliferative response to balloon injury was reduced by 70% and the area of vascular wall covered by lesion formation was decreased by 45% in rats treated with the angiotensin-converting enzyme inhibitor cilazapril. Other antihypertensive agents were much less active when tested for suppression of intimal hyperplasia after balloon injury: verapamil 0%, minoxidil 4% and hydralazine 34%. For cilazapril at the dose of 10 mg/kg per day, approximately 20% greater suppression of intimal hyperplasia was seen when the treatment was started 6 days before balloon injury. Treatment of rats fron the time of balloon catheterization with both cilazapril (10 mg/kg per day) and heparin infusion (0.3 mg/kg per h) resulted in essentially complete (> 90%) inhibition of intimal hyperplasia. These data indicate that the angiotensin-converting enzyme inhibitor cilazapril specifically inhibits the proliferative response to balloon injury and that heparin and cilazapril inhibit intimal hyperplasia through different mechanisms. The data also suggest that the use of pharmacologic combinations may have therapeutic usefulness to prevent late restenosis after coronary angioplasty.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalJournal of the American College of Cardiology
Volume17
Issue number6 SUPPL. 2
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Cilazapril
Tunica Intima
Angiotensin-Converting Enzyme Inhibitors
Hyperplasia
Blood Vessels
Angioplasty
Wounds and Injuries
Catheterization
Heparin
Coronary Restenosis
Minoxidil
Hydralazine
Vascular System Injuries
Verapamil
Antihypertensive Agents
Smooth Muscle Myocytes
Extracellular Matrix
Therapeutics
Cell Proliferation

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Suppression of the vascular response to injury : The role of angiotensin-converting enzyme inhibitors. / Powell, Jerry S; Muller, Rita K M; Baumgartner, Hans R.

In: Journal of the American College of Cardiology, Vol. 17, No. 6 SUPPL. 2, 1991, p. 137-142.

Research output: Contribution to journalArticle

@article{39ece16f720d43b7a9bbcc06f458ce8e,
title = "Suppression of the vascular response to injury: The role of angiotensin-converting enzyme inhibitors",
abstract = "Smooth muscle cell proliferation and formation of extracellular matrix are parts of the repair process after vascular injury. Similar processes occur after coronary angioplasty and, in approximately 33{\%} of vessels, lead to intimal hyperplasia and vascular restenosis within 6 months after angioplasty. In a rat model of balloon catheterization, the proliferative response to balloon injury was reduced by 70{\%} and the area of vascular wall covered by lesion formation was decreased by 45{\%} in rats treated with the angiotensin-converting enzyme inhibitor cilazapril. Other antihypertensive agents were much less active when tested for suppression of intimal hyperplasia after balloon injury: verapamil 0{\%}, minoxidil 4{\%} and hydralazine 34{\%}. For cilazapril at the dose of 10 mg/kg per day, approximately 20{\%} greater suppression of intimal hyperplasia was seen when the treatment was started 6 days before balloon injury. Treatment of rats fron the time of balloon catheterization with both cilazapril (10 mg/kg per day) and heparin infusion (0.3 mg/kg per h) resulted in essentially complete (> 90{\%}) inhibition of intimal hyperplasia. These data indicate that the angiotensin-converting enzyme inhibitor cilazapril specifically inhibits the proliferative response to balloon injury and that heparin and cilazapril inhibit intimal hyperplasia through different mechanisms. The data also suggest that the use of pharmacologic combinations may have therapeutic usefulness to prevent late restenosis after coronary angioplasty.",
author = "Powell, {Jerry S} and Muller, {Rita K M} and Baumgartner, {Hans R.}",
year = "1991",
doi = "10.1016/0735-1097(91)90950-E",
language = "English (US)",
volume = "17",
pages = "137--142",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6 SUPPL. 2",

}

TY - JOUR

T1 - Suppression of the vascular response to injury

T2 - The role of angiotensin-converting enzyme inhibitors

AU - Powell, Jerry S

AU - Muller, Rita K M

AU - Baumgartner, Hans R.

PY - 1991

Y1 - 1991

N2 - Smooth muscle cell proliferation and formation of extracellular matrix are parts of the repair process after vascular injury. Similar processes occur after coronary angioplasty and, in approximately 33% of vessels, lead to intimal hyperplasia and vascular restenosis within 6 months after angioplasty. In a rat model of balloon catheterization, the proliferative response to balloon injury was reduced by 70% and the area of vascular wall covered by lesion formation was decreased by 45% in rats treated with the angiotensin-converting enzyme inhibitor cilazapril. Other antihypertensive agents were much less active when tested for suppression of intimal hyperplasia after balloon injury: verapamil 0%, minoxidil 4% and hydralazine 34%. For cilazapril at the dose of 10 mg/kg per day, approximately 20% greater suppression of intimal hyperplasia was seen when the treatment was started 6 days before balloon injury. Treatment of rats fron the time of balloon catheterization with both cilazapril (10 mg/kg per day) and heparin infusion (0.3 mg/kg per h) resulted in essentially complete (> 90%) inhibition of intimal hyperplasia. These data indicate that the angiotensin-converting enzyme inhibitor cilazapril specifically inhibits the proliferative response to balloon injury and that heparin and cilazapril inhibit intimal hyperplasia through different mechanisms. The data also suggest that the use of pharmacologic combinations may have therapeutic usefulness to prevent late restenosis after coronary angioplasty.

AB - Smooth muscle cell proliferation and formation of extracellular matrix are parts of the repair process after vascular injury. Similar processes occur after coronary angioplasty and, in approximately 33% of vessels, lead to intimal hyperplasia and vascular restenosis within 6 months after angioplasty. In a rat model of balloon catheterization, the proliferative response to balloon injury was reduced by 70% and the area of vascular wall covered by lesion formation was decreased by 45% in rats treated with the angiotensin-converting enzyme inhibitor cilazapril. Other antihypertensive agents were much less active when tested for suppression of intimal hyperplasia after balloon injury: verapamil 0%, minoxidil 4% and hydralazine 34%. For cilazapril at the dose of 10 mg/kg per day, approximately 20% greater suppression of intimal hyperplasia was seen when the treatment was started 6 days before balloon injury. Treatment of rats fron the time of balloon catheterization with both cilazapril (10 mg/kg per day) and heparin infusion (0.3 mg/kg per h) resulted in essentially complete (> 90%) inhibition of intimal hyperplasia. These data indicate that the angiotensin-converting enzyme inhibitor cilazapril specifically inhibits the proliferative response to balloon injury and that heparin and cilazapril inhibit intimal hyperplasia through different mechanisms. The data also suggest that the use of pharmacologic combinations may have therapeutic usefulness to prevent late restenosis after coronary angioplasty.

UR - http://www.scopus.com/inward/record.url?scp=0025905888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025905888&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(91)90950-E

DO - 10.1016/0735-1097(91)90950-E

M3 - Article

VL - 17

SP - 137

EP - 142

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6 SUPPL. 2

ER -